Merck cancer vaccine a priority for Immunovaccine

Immunovaccine (TSX-V:IMV) is making a new clinical-stage cancer vaccine that it acquired from Germany’s Merck KGaA in June a development and regulatory priority as it formulates Merck’s survivin-based vaccine with its own DepoVax delivery system. “The reason we’re excited about it is that the National Cancer Institute ranks survivin as one of the top 25 [...]

Medicago in vaccine MOU in Indonesia

Medicago (TSX:MDG) has signed a memorandum of understanding with Indonesia’s PT Bio Farma to develop select vaccine targets of mutual interest, with the final goal of establishing a partnership to build a Medicago plant-based manufacturing facility in the country. “This agreement confirms the suitability of our technology to support vaccine development in countries where manufacturing [...]

Medicago to present at WHO meeting

Medicago (TSX:MDG) will present its Phase 1 clinical findings of the first plant-made influenza vaccine to be tested in humans at a meeting this week of the World Health Organization, evaluating pandemic influenza prototype vaccines in clinical trials. “It is a privilege to be among a select group of leading vaccine companies invited to present [...]

Waiting on Medicago trial results

In a New Idea of Interest report on Medicago (TSX-V:MDG), Dundee Securities said that if Phase 1 results for its lead H5N1 avian vaccine are positive in December, the company could “establish a leading position in the global effort to find a superior vaccine-production technology.” Analyst David Martin rates the stock “buy (speculative risk)” but [...]